These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 33317348)
1. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review. Ruan Z; Yang L; Shi H; Yue X; Wang Y; Liang M; Hu H Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):221-233. PubMed ID: 33317348 [No Abstract] [Full Text] [Related]
2. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765 [TBL] [Abstract][Full Text] [Related]
3. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244 [TBL] [Abstract][Full Text] [Related]
4. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244 [No Abstract] [Full Text] [Related]
5. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden. Ericsson Å; Fridhammar A J Med Econ; 2019 Oct; 22(10):997-1005. PubMed ID: 31044636 [No Abstract] [Full Text] [Related]
6. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. Goldman JD J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492 [TBL] [Abstract][Full Text] [Related]
7. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)? Doggrell SA Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603 [TBL] [Abstract][Full Text] [Related]
8. Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy. Bzowyckyj A J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):7-16. PubMed ID: 32910488 [TBL] [Abstract][Full Text] [Related]
9. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199 [No Abstract] [Full Text] [Related]
10. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. Patel D J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489 [TBL] [Abstract][Full Text] [Related]
11. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522 [TBL] [Abstract][Full Text] [Related]
12. Semaglutide once-weekly: improved efficacy with a new safety warning. Coon SA; Crannage EF; Kerwin LC; Guyton JE Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224 [TBL] [Abstract][Full Text] [Related]
14. Safety of injectable semaglutide for type 2 diabetes. Peter R; Bain SC Expert Opin Drug Saf; 2020 Jul; 19(7):785-798. PubMed ID: 32428416 [TBL] [Abstract][Full Text] [Related]
15. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. Tuchscherer RM; Thompson AM; Trujillo JM Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006 [TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. Trujillo J J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):43-60. PubMed ID: 32910487 [TBL] [Abstract][Full Text] [Related]
17. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. Gallwitz B; Giorgino F Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Lau DCW; Batterham RL; le Roux CW Expert Rev Clin Pharmacol; 2022 Mar; 15(3):251-267. PubMed ID: 35466848 [TBL] [Abstract][Full Text] [Related]
19. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. Cornell S J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):17-27. PubMed ID: 32910490 [TBL] [Abstract][Full Text] [Related]
20. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? Gogineni P; Melson E; Papamargaritis D; Davies M Expert Opin Pharmacother; 2024 May; 25(7):801-818. PubMed ID: 38753454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]